Strides Shasun to launch allergy drug in the US

Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US.

“The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player,” the company said.

“The product is ready for launch immediately and as in the case of OTC products, the market formation takes time and the Company expects to have an important market share in approximately six months,” it added.

The product will be manufactured at the Company’s flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

This is the first approval for a Softgel product after the recent US FDA inspection at the Company’s Bangalore facility.

Cetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching.

It works by blocking a Certain natural Substance (histamine) that your body makes during an allergic reaction.

Strides Shasun is a pharmaceutical company headquartered in Bangalore.